OBI Pharma, Inc. (TPEX:4174)

Market Cap	10.27B
Revenue (ttm)	62.68M
Net Income (ttm)	-2.31B
Shares Out	262.97M
EPS (ttm)	-9.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,107,918
Average Volume	1,685,181
Open	39.40
Previous Close	39.05
Day's Range	38.30 - 39.65
52-Week Range	35.00 - 92.90
Beta	0.53
RSI	32.44
Earnings Date	May 13, 2025

About OBI Pharma

OBI Pharma, Inc., a clinical stage oncology company, research and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company’s pipeline products include Adagloxad simolenin which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424 which has completed phase 2 for the treatment of liver hepatocellular carcinoma and acute lymphocytic leukemia; OBI-992 which is in phase 1 for the treatment of so...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4174

Financial Performance

In 2024, OBI Pharma's revenue was 62.68 million, an increase of 50.85% compared to the previous year's 41.55 million. Losses were -2.31 billion, 120.7% more than in 2023.